MERCK
Merck, a leading science and technology company, today announced the signing of a definitive agreement to acquire for US$ 600 million. Mirus Bio, part of Gamma Biosciences, is a life science company based in Madison, Wisconsin, USA that specializes in the development and commercialization of transfection reagents, such as TransIT-VirusGEN®. Transfection reagents play a critical role in the production of viral vector-based gene therapies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240523399185/en/
Merck operators monitoring viral vector production in a bioreactor in Merck's Carlsbad, California manufacturing facility. (Photo: Business Wire)
“Viral vector-based cell and gene therapies have demonstrated their potential with more than 20 approvals over the last 10 years1 and will continue to advance, with a projected growth of 30 percent until 20282,” said Matthias Heinzel, Member of the Executive Board of Merck and CEO Life Science. “This acquisition, combined with our comprehensive portfolio, enables us to provide a truly differentiated and integrated offering to meet the growing demand for these life-saving therapies.”
“We have been driving innovation in nucleic acid delivery for two decades,” said Dale Gordon, CEO of Mirus Bio. “Merck’s broad portfolio, scale and global reach, combined with our leading transfection reagents, will help take our business to even greater heights and allow us to serve more customers, and ultimately patients, worldwide.”
Merck’s Process Solutions business offers one of the broadest product portfolios in the industry and provides flexible solutions for viral vector manufacturing to advance cell and gene therapies from preclinical through commercial production. This comprehensive portfolio includes cell lines, cell culture media, processing chemicals and buffers, enzymes, as well as systems, filters, hardware and consumables to support every step of the viral vector manufacturing processes. Merck’s expertise and portfolio covers a variety of viral vector types, including adeno-associated virus, lentivirus, and adenovirus. Additionally, Merck’s Life Science Services business offers both contract testing services and a suite of comprehensive CDMO services for viral vector manufacturing, leveraging three decades of experience supporting cell and gene therapies to de-risk the path to commercialization.
This deal is anticipated to close in Q3 of 2024 and is subject to regulatory clearance and other customary closing conditions.
All Merck press releases are distributed by e-mail at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
About Merck
Merck, a leading science and technology company, operates across life science, healthcare and electronics. Around 63,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2023, Merck generated sales of € 21 billion in 65 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.
2 EvaluatePharma 2023
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240523399185/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Guardant Health and Collaborators to Present New Data Across the Cancer Care Continuum at ESMO 202515.10.2025 22:57:00 CEST | Press release
15 abstracts spanning advancements in early detection of recurrence, tumor profiling, and therapy response monitoringPresentations highlight the power of Guardant Health’s blood-based assays to reduce treatment burden and improve disease monitoring across multiple cancer types Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that new data from across its oncology portfolio will be presented in 15 accepted abstracts at the European Society for Medical Oncology (ESMO) Congress 2025, taking place October 17–21 in Berlin, Germany. These presentations span the cancer care treatment continuum, from minimal residual disease (MRD) detection and recurrence monitoring to advanced-stage tumor profiling and therapy response assessment. Guardant Health’s accepted abstracts span multiple tumor types, including lung, colorectal, breast, head and neck, and cancers of unknown primary. Together, they underscore the company’s commitment to harnessing cutting-edge
Greenland Resources Signs Mandate Agreement With European Bank15.10.2025 21:06:00 CEST | Press release
Greenland Resources A/S, a fully owned Greenlandic subsidiary of Greenland Resources Inc. (Cboe CA: MOLY | FSE: M0LY) (“Greenland Resources” or the “Company”) is pleased to announce the Company has signed a mandate letter with a major German Bank (the “Bank”) to act as the Export Credit Agency (“ECA”) Coordinator for the Project. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251015159644/en/ The ECA Coordinator role covers the relevant tasks up to debt financial close. The Bank has extensive experience in acting as the ECAs Coordinator in project financings worldwide, as well as being one of Europe’s most prestigious institutions. The Bank will now be in a position to start working with some of the ECA’s discussed in previous press releases (primarily EKN, Finnvera, and EIFO). The Company’s debt part of the Capex is around US$750 million. Mandating the Bank complements the Company’s strategy to increase EU and specifically
Interactive Brokers Launches Ask IBKR: AI Tool Delivers Instant Portfolio Answers15.10.2025 16:00:00 CEST | Press release
New Natural Language Interface Helps Clients Analyze Holdings, Performance, and Allocation in Seconds Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, today announced the launch of Ask IBKR, an AI-powered tool that delivers instant portfolio insights through natural language queries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251015991473/en/ “With Ask IBKR, we’re introducing a natural language-based way for investors to interact with their portfolio data,” said Milan Galik, Chief Executive Officer at Interactive Brokers. “Instead of navigating across screens, clients can simply ask, ‘What sector am I underweight compared to the S&P 500?’ and get an instant, visualized answer.” Categories of queries include: Portfolio Metrics: Compare performance against benchmarks, identify valuation changes over time, and highlight periods of outperformance or underperformance Allocation Analysis: Analyze sect
Multiply Group Announces Plans to Acquire 2PointZero and Ghitha Holding via Share Swap15.10.2025 15:36:00 CEST | Press release
The proposed acquisition forms part of Multiply Group’s broader strategy to build scale, enhance portfolio synergies, and drive long-term value.2PointZero brings scalable assets across energy, mining and financial services, while Ghitha Holding contributes a diversified food and agriculture platform.The transaction remains subject to shareholder and regulatory approvals, with further details to be announced upon completion of the review process. Multiply Group (ADX: MULTIPLY), the Abu Dhabi-based investment holding company that invests in and operates businesses globally, today announced that its Board has approved a proposal to acquire 2PointZero and Ghitha Holding through a share swap transaction. Under the proposed terms, Multiply Group would offer shares to acquire 2PointZero and Ghitha Holding, followed by the issuance of new shares to complete the transaction. The transaction is currently under review and remains subject to shareholder and regulatory approvals. 2PointZero is a tr
Svante Hails Nobel Prize in Chemistry, Validating Metal-Organic Framework Technology is Critical for Commercial Carbon Capture15.10.2025 15:30:00 CEST | Press release
The Nobel Prize for Chemistry has awarded scientists for their work in metal-organic frameworks (MOFs), for their high capacity and selectivity for captured gases, including CO2. The CALF-20 MOF used in Svante’s filters for carbon capture and removal, was highlighted in the award announcement. Svante, a leader in solid sorbent-based carbon capture and removal filter technology, celebrated the announcement of the 2025 Nobel Prize in Chemistry last week, which honored scientists Susumu Kitagawa, Richard Robson and Omar Yaghi for their groundbreaking work in the metal-organic framework (MOF) field. The Royal Swedish Academy of Sciences awarded the prize for the development of MOFs, citing their "enormous potential" and unique molecular architecture that creates spacious, porous materials capable of capturing and storing specific substances, including carbon dioxide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251015855374/
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom